Subcutaneous · Amylin analog
AZD6234
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
11
Active
7
Recruiting
5
Completed
4
Sites
123
Countries
9
Endpoints
207
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
6
Phase 1/2
1
Phase 2
4
Trials by status
Recruiting
5
Active, not recruiting
2
Completed
4
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
106
Weight & body composition
31
Glycemic / diabetes
27
Other (unclassified)
24
MASH / liver
10
Other clinical outcomes
6
Cardiometabolic biomarkers
3
Most-measured metrics
Top 20 metrics across this asset's endpoints
Body weight, % changeWeight
1
≥5% weight-loss respondersWeight
1
≥10% weight-loss respondersWeight
1
Body weight, absolute change (kg)Weight
1
HbA1c, changeGlycemic
1
Plasma concentration (steady state)Safety/PK
1
Fasting glucose, changeGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11